Status:
UNKNOWN
Primary Prevention of Infections Related to Chambers Implantable Catheter by a Taurolodine Lock in Patients With Cancer Receiving Parenteral Nutrition
Lead Sponsor:
Hospices Civils de Lyon
Conditions:
Cancer
Infection
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
The therapeutic management of patients with cancer often requires the establishment of a chamber implantable catheter. Infections are the main complication of these catheters. These infections may be ...
Eligibility Criteria
Inclusion
- Patients aged 18 years and over
- Patients with solid cancer
- Patients with implantable catheter
- Patients receiving parenteral nutrition
- Patient affiliated to a social security scheme or beneficiary of such a regime
Exclusion
- Patients refusing to participate in the protocol
- Patients already receiving preventive lock of IRCIC
- Known citrate or (cyclo) allergy -taurolidine
- Patients taking other drugs with known contraindications against the citrate or cyclotaurolidine.
- Participation in another protocol for the prevention of infections associated with central venous catheters
- Patients who did not sign the consent
- Patient with a status of socio-legal protection
Key Trial Info
Start Date :
January 1 2015
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
May 1 2017
Estimated Enrollment :
70 Patients enrolled
Trial Details
Trial ID
NCT02255318
Start Date
January 1 2015
End Date
May 1 2017
Last Update
October 28 2016
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Hôpital Edouard Herriot
France, Lyon, France, 69003
2
Hôpital de la Croix Rousse
France, France
3
Groupement Hospitalier Lyon Sud
Pierre-Bénite, France